GLP-1 weight loss is not slowing down. Wegovy’s maker, Novo Nordisk, has received FDA approval for a higher-dose version of the injectable, signaling a new phase in how far these treatments can go.
In clinical trials, patients using the higher-dose formulation saw average weight loss of around 20 percent or more, with some individuals reaching even higher numbers (up to 25 percent in some) that continue to shift expectations around what’s possible with medical weight loss.
“We are excited to bring Wegovy HD to adults with obesity who are looking for powerful weight loss,” said Jamey Millar, executive vice president of U.S. operations at Novo Nordisk, in a press release.
A Higher Dose, for the Right Patient
The Wegovy most patients know today is a once-weekly injectable at a 2.4 mg dose. The higher-dose version increases that to 7.2 mg, offering a new option for patients who have already tolerated the standard dose and are looking to continue progressing. Importantly, this option is intended for patients already using GLP-1 therapy.
The safety profile is similar to what providers and patients already know from GLP-1 medications, with common side effects including nausea, vomiting, diarrhea, constipation and fatigue. As with all treatments in this category, prescribing information includes important safety considerations that providers review before starting treatment.
As more GLP-1 options and dosing levels roll out, providers have more ways to tailor treatment, and patients have more options than ever before.
